J.‐P. Lacour

23.9k total citations · 3 hit papers
402 papers, 10.2k citations indexed

About

J.‐P. Lacour is a scholar working on Dermatology, Epidemiology and Oncology. According to data from OpenAlex, J.‐P. Lacour has authored 402 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 135 papers in Dermatology, 79 papers in Epidemiology and 77 papers in Oncology. Recurrent topics in J.‐P. Lacour's work include Dermatology and Skin Diseases (53 papers), Autoimmune Bullous Skin Diseases (40 papers) and Psoriasis: Treatment and Pathogenesis (38 papers). J.‐P. Lacour is often cited by papers focused on Dermatology and Skin Diseases (53 papers), Autoimmune Bullous Skin Diseases (40 papers) and Psoriasis: Treatment and Pathogenesis (38 papers). J.‐P. Lacour collaborates with scholars based in France, United States and Germany. J.‐P. Lacour's co-authors include Thierry Passeron, J.‐P. Ortonne, Philippe Bahadoran, Monique G. Lê, Éric Fontas, D Sarrazin, Henri Montaudié, G Contesso, Paul Hofman and C. Chiavérini and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

J.‐P. Lacour

383 papers receiving 9.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer

1989 434 citations D Sarrazin, G Contesso et al. profile →
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

2017 392 citations Kim Papp, Andrew Blauvelt et al. profile →
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis

2020 173 citations J.‐P. Lacour et al. profile →

Peers

Countries citing papers authored by J.‐P. Lacour

Since Specialization

Citations

This map shows the geographic impact of J.‐P. Lacour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.‐P. Lacour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.‐P. Lacour more than expected).

Fields of papers citing papers by J.‐P. Lacour

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.‐P. Lacour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.‐P. Lacour. The network helps show where J.‐P. Lacour may publish in the future.

Co-authorship network of co-authors of J.‐P. Lacour

This figure shows the co-authorship network connecting the top 25 collaborators of J.‐P. Lacour. A scholar is included among the top collaborators of J.‐P. Lacour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.‐P. Lacour. J.‐P. Lacour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial 2023 ·Journal of the American Academy of Dermatology ·Joseph F. Merola, Lawrence Charles Parish, Lyn Guenther, Charles Lynde, J.‐P. Lacour, Petra Staubach, Sue Cheng, Maria Paris, Hernàn Picard, (unknown), (unknown), Mindy Chen, Kim Papp	13
2	IgE Depletion with Ligelizumab Does Not Significantly Improve Clinical Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis 2023 ·Journal of Investigative Dermatology ·Christine Bangert, Christian Loesche, Hans Skvara, Regina Fölster‐Holst, J.‐P. Lacour, Julie Jones, Patrick Burnett, Natalija Novak, Georg Stingl	10
3	Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2 2022 ·Journal of the European Academy of Dermatology and Venereology ·Anthony P. Fernandez, E. Daudén, Sascha Gerdes, Mark Lebwohl, Alan Menter, C. Leonardi, Melinda Gooderham, Kurt Gebauer, Yayoi Tada, J.‐P. Lacour, Luca Bianchi, Alexander Egeberg, Ignasi Pau‐Charles, Alan M. Mendelsohn, Stephen J. Rozzo, Nehal N. Mehta	15
4	Annular lipoatrophy of the ankle: Four new pediatric cases and a review of the literature 2021 ·Pediatric Dermatology ·(unknown), É. Tournier, Laurence Lamant, (unknown), Alain Taı̈eb, Christine Labrèze, (unknown), Sébastien Lepreux, C. Chiavérini, J.‐P. Lacour, Nathalie Cardot‐Leccia, C. Bédane, (unknown), (unknown), J. Mazereeuw‐Hautier	1
5	Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway 2019 ·Oncogene ·Moeez Rathore, Christophe A. Girard, Mickaël Ohanna, Mélanie Tichet, (unknown), Esther García, Frédéric Larbret, Maéva Gesson, Stéphane Audebert, J.‐P. Lacour, Henri Montaudié, Virginie Prod’homme, Sophie Tartare‐Deckert, Marcel Deckert	64
6	Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches 2018 ·British Journal of Dermatology ·Andrew Blauvelt, J.‐P. Lacour, Joseph F. Fowler, Jeffrey M Weinberg, Dimitar Gospodinov, (unknown), (unknown), Alison Balfour, C. Leonardi	109
7	Epidermolysis bullosa simplex generalized severe induces a T helper 17 response and is improved by apremilast treatment 2018 ·British Journal of Dermatology ·E. Castela, Meri K. Tulić, Aurore Rozières, E. Bourrat, Jean‐François Nicolas, Jean Kanitakis, P. Vabres, D. Bessis, J. Mazereeuw‐Hautier, Fanny Morice‐Picard, David Baty, F. Bérard, J.‐P. Lacour, Thierry Passeron, C. Chiavérini	38
8	Eruptive lingual papillitis with household transmission: a prospective clinical study 2004 ·British Journal of Dermatology ·Olivier Roux, J.‐P. Lacour, (unknown)	7
9	Carcinogenesis of basal cell carcinomas: genetics and molecular mechanisms 2002 ·British Journal of Dermatology ·J.‐P. Lacour	130
10	[Dermatoses of the premature child]. 1999 ·PubMed ·J.‐P. Lacour, P Boutté	3
11	55 días en Pekín 1998 ·PubMed ·Pierre Marty, J.‐P. Lacour, Francine Pratlong, Christophe Perrin, (unknown), (unknown)	13
12	Escherichia coli cellulitis: two cases. 1992 ·Acta Dermato Venereologica ·J. Castanet, J.‐P. Lacour, C Perrin, Isaac Bodokh, (unknown), J.‐P. Ortonne	18
13	Is it useful to remove internal mammary nodes in operable breast cancer? 1987 ·PubMed ·J.‐P. Lacour, (unknown), Catherine Hill, A. Kramar, G Contesso, D Sarrazin	80
14	Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomised trial. 1984 ·BMJ ·J.‐P. Lacour, F Lacour, Alfred Spira, M Michelson, Jean‐Yves Petit, G Delage, D Sarrazin, G Contesso, (unknown)	32
15	Enhancement of Interferon-mediated Protein Kinase in Mouse and Human Plasma in Response to Treatment with Polyadenylic–Polyuridylic Acid (Poly A:Poly U) 1982 ·Journal of Interferon Research ·Ara G. Hovanessian, Yves Rivière, Luc Montagnier, M Michelson, J.‐P. Lacour, Fanny Lacour	20
16	[Regional lymph node dissection in malignant melanomas of the skin. Indications and results (author's transl)]. 1978 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·J.‐P. Lacour, (unknown), H Sancho, (unknown), M Prade	1
17	[Replacement of the ureter with a prosthesis in cancer patients. Apropos of 38 cases]. 1977 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Gérard Michel, J.‐P. Lacour, (unknown)	1
18	Ulcères gastriques précoces après radiothérapie. 1973 ·(unknown), F. Eschwège, (unknown), G. Michel, (unknown), M. Schlienger, J.‐P. Lacour	1
19	135 laparotomies et splénectomies pour maladie de Hodgkin. 1971 ·Bulletin du Cancer ·Jeanne Amiel, J.‐P. Lacour, R Gérard-Marchant, (unknown), (unknown), (unknown), M. Schlienger, P Pouillart, (unknown), M Tubiana, (unknown)	4
20	Cancérisation précoce chez la souris par injection de préparations contenant l'acide ribonucléique de tumeurs homologues. 1959 ·Comptes rendus hebdomadaires des séances de l Académie des sciences ·J. Huppert, (unknown), J.‐P. Lacour, Josée Harel	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact